Ilko L Maier1, André Karch2, Christina Lipke3, Daniel Behme3, Anastasios Mpotsaris4, Christoph Kabbasch4, Thomas Liebig4, Andrea Faymonville5, Arno Reich6, Omid Nikoubashman7, Jan-Hendrik Buhk8, Patrick von Schoenfeld9, Werner Weber10, Rafael T Mikolajczyk2, Mathias Bähr11, Michael Knauth3, Kai Kallenberg3, Jan Liman12. 1. Department of Neurology, University Medicine Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany. ilko.maier@med.uni-goettingen.de. 2. Research group Epidemiological and Statistical Methods (ESME), Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany. 3. Department of Neuroradiology, University Medicine Göttingen, Göttingen, Germany. 4. Department of Neuroradiology, University Hospital Cologne, Cologne, Germany. 5. Department of Neurosurgery, University Hospital Cologne, Cologne, Germany. 6. Department of Neurology, University Hospital Aachen, Aachen, Germany. 7. Department of Neuroradiology, University Hospital Aachen, Aachen, Germany. 8. Department of Neuroradiology, , University Hospital Hamburg-Eppendorf, Hamburg-Eppendorf, Germany. 9. Department of Neuroradiology, Klinikum Vest, Recklinghausen, Germany. 10. Department of Neuroradiology, University Hospital Knappschaftskrankenhaus Bochum, Bochum, Germany. 11. Department of Neurology, University Medicine Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany. 12. Department of Neurology, University Medicine Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany. jliman@gwdg.de.
Abstract
PURPOSE: Two recent randomized controlled trials (RCT) consistently showed superiority of aggressive medical treatment versus percutaneous transluminal angioplasty and stenting (PTAS) in patients with intracranial artery stenosis. Patients with symptomatic basilar stenosis have a higher long-term risk of recurrent stroke compared to patients with anterior circulation stenosis but no study has specifically focused on the role of PTAS in this subgroup. The aim of our study was to investigate the subgroup of patients with symptomatic basilar artery stenosis to find evidence for the feasibility of a future clinical trial. METHODS: Patients with ischemic stroke caused by a symptomatic basilar stenosis and admitted to five German tertiary care hospitals were included in this multicenter effectiveness study. Primary outcome was a composite endpoint of stroke recurrence, clinically relevant restenosis, progression and death. Shared frailty Cox regression models were used to compare outcome rates between groups. RESULTS: Of the 139 patients included in the study 79 (57 %) underwent PTAS and 60 (43 %) conservative treatment alone. The median follow-up period was 300 (IQR 18-738) days. Risks of the primary composite outcome (hazard ratio HR 0.49, 95 % confidence interval CI 0.25-0.97, p = 0.039) and of the key secondary outcomes recurrent stroke (HR 0.42, 95 % CI 0.19-0.95, p = 0.037) and clinically relevant restenosis/progression (HR 0.12, 95 % CI 0.03-0.59, p = 0.009) were lower in patients with PTAS compared to conservative treatment. There was no difference in all-cause mortality between groups (HR 0.98, 95 % CI 0.19-5.09, p = 0.979). CONCLUSION: In this retrospective study we could not reproduce the findings from large RCTs on intracranial stenting. Our data could be considered as a basis for a prospective study on patient selection for PTAS in the basilar artery.
PURPOSE: Two recent randomized controlled trials (RCT) consistently showed superiority of aggressive medical treatment versus percutaneous transluminal angioplasty and stenting (PTAS) in patients with intracranial artery stenosis. Patients with symptomatic basilar stenosis have a higher long-term risk of recurrent stroke compared to patients with anterior circulation stenosis but no study has specifically focused on the role of PTAS in this subgroup. The aim of our study was to investigate the subgroup of patients with symptomatic basilar artery stenosis to find evidence for the feasibility of a future clinical trial. METHODS:Patients with ischemic stroke caused by a symptomatic basilar stenosis and admitted to five German tertiary care hospitals were included in this multicenter effectiveness study. Primary outcome was a composite endpoint of stroke recurrence, clinically relevant restenosis, progression and death. Shared frailty Cox regression models were used to compare outcome rates between groups. RESULTS: Of the 139 patients included in the study 79 (57 %) underwent PTAS and 60 (43 %) conservative treatment alone. The median follow-up period was 300 (IQR 18-738) days. Risks of the primary composite outcome (hazard ratio HR 0.49, 95 % confidence interval CI 0.25-0.97, p = 0.039) and of the key secondary outcomes recurrent stroke (HR 0.42, 95 % CI 0.19-0.95, p = 0.037) and clinically relevant restenosis/progression (HR 0.12, 95 % CI 0.03-0.59, p = 0.009) were lower in patients with PTAS compared to conservative treatment. There was no difference in all-cause mortality between groups (HR 0.98, 95 % CI 0.19-5.09, p = 0.979). CONCLUSION: In this retrospective study we could not reproduce the findings from large RCTs on intracranial stenting. Our data could be considered as a basis for a prospective study on patient selection for PTAS in the basilar artery.
Authors: Marc I Chimowitz; Michael J Lynn; Harriet Howlett-Smith; Barney J Stern; Vicki S Hertzberg; Michael R Frankel; Steven R Levine; Seemant Chaturvedi; Scott E Kasner; Curtis G Benesch; Cathy A Sila; Tudor G Jovin; Jose G Romano Journal: N Engl J Med Date: 2005-03-31 Impact factor: 91.245
Authors: Ahmad R Abuzinadah; Mohammed H Alanazy; Mohammed A Almekhlafi; Yanjune Duan; Haifeng Zhu; Mikael Mazighi; Helmi L Lutsep; Tyrone Donnon; Michael D Hill Journal: J Neurointerv Surg Date: 2014-12-11 Impact factor: 5.836
Authors: Marc I Chimowitz; Michael J Lynn; Colin P Derdeyn; Tanya N Turan; David Fiorella; Bethany F Lane; L Scott Janis; Helmi L Lutsep; Stanley L Barnwell; Michael F Waters; Brian L Hoh; J Maurice Hourihane; Elad I Levy; Andrei V Alexandrov; Mark R Harrigan; David Chiu; Richard P Klucznik; Joni M Clark; Cameron G McDougall; Mark D Johnson; G Lee Pride; Michel T Torbey; Osama O Zaidat; Zoran Rumboldt; Harry J Cloft Journal: N Engl J Med Date: 2011-09-07 Impact factor: 91.245
Authors: J Christopher Wehman; Ricardo A Hanel; Charles A Guidot; Lee R Guterman; L Nelson Hopkins Journal: J Interv Cardiol Date: 2004-08 Impact factor: 2.279
Authors: Louis R Caplan; Robert J Wityk; Thomas A Glass; Jorge Tapia; Ladislav Pazdera; Hui-Meng Chang; Phillip Teal; John F Dashe; Claudia J Chaves; Joan C Breen; Kostas Vemmos; Pierre Amarenco; Barbara Tettenborn; Megan Leary; Conrad Estol; L Dana Dewitt; Michael S Pessin Journal: Ann Neurol Date: 2004-09 Impact factor: 10.422